LXRX (Lexicon Pharmaceuticals) Long-Term Debt: $49.68 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LXRX Lexicon Pharmaceuticals Inc LXRX
39 GF Score
Price $2.46
! 5 Warning Signs
View Full Analysis

What is Lexicon Pharmaceuticals Long-Term Debt?

Lexicon Pharmaceuticals LXRX +5.36% 39 Long-Term Debt is $49.68 Mil as of Mar. 2026. GuruFocus rates LXRX with a GF Score™ of 39/100. The stock has 5 warning signs investors should review.

Lexicon Pharmaceuticals's Long-Term Debt for the quarter that ended in Mar. 2026 was $49.68 Mil.

Lexicon Pharmaceuticals's quarterly Long-Term Debt declined from Sep. 2025 ($56.51 Mil) to Dec. 2025 ($49.41 Mil) but then increased from Dec. 2025 ($49.41 Mil) to Mar. 2026 ($49.68 Mil).

Lexicon Pharmaceuticals's annual Long-Term Debt increased from Dec. 2023 ($99.51 Mil) to Dec. 2024 ($100.30 Mil) but then declined from Dec. 2024 ($100.30 Mil) to Dec. 2025 ($49.41 Mil).

Lexicon Pharmaceuticals  (NAS:LXRX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Lexicon Pharmaceuticals Long-Term Debt Related Terms

Lexicon Pharmaceuticals Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Lexicon Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexicon Pharmaceuticals Long-Term Debt Chart

Lexicon Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 48.58 99.51 100.30 49.41

Lexicon Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.64 56.11 56.51 49.41 49.68
LXRX
39GF Score
Lexicon Pharmaceuticals Inc LXRX
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $49.68 Mil mean?
Lexicon Pharmaceuticals (LXRX) has a Long-Term Debt of $49.68 Mil as of Mar. 2026.
Is Lexicon Pharmaceuticals' Long-Term Debt too high?
Lexicon Pharmaceuticals' current Long-Term Debt is $49.68 Mil. Overall, Lexicon Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Lexicon Pharmaceuticals' Long-Term Debt compare to EYPT and OLMA?
Lexicon Pharmaceuticals' Long-Term Debt of $49.68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Lexicon Pharmaceuticals's current Long-Term Debt is $49.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexicon Pharmaceuticals stock overvalued right now?
Lexicon Pharmaceuticals (LXRX) has a current Long-Term Debt of $49.68 Mil. The current Long-Term Debt is $49.68 Mil. Lexicon Pharmaceuticals' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Lexicon Pharmaceuticals (LXRX), the current Long-Term Debt is $49.68 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lexicon Pharmaceuticals Business Description

Address 2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
39GF Score

Get the complete analysis for LXRX

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.46
Price